Ardelyx, Inc. (NASDAQ:ARDX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Ardelyx, Inc. (NASDAQ:ARDX) have been given a consensus rating of “Moderate Buy” by the twelve analysts that are currently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, nine have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $15.30.

ARDX has been the topic of a number of recent analyst reports. HC Wainwright restated a “buy” rating and issued a $13.00 target price on shares of Ardelyx in a research note on Friday. TD Cowen dropped their price target on Ardelyx from $13.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday. BTIG Research cut their price objective on shares of Ardelyx from $17.00 to $14.00 and set a “buy” rating on the stock in a research report on Friday. Weiss Ratings lowered Ardelyx from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 29th. Finally, LADENBURG THALM/SH SH began coverage on shares of Ardelyx in a report on Tuesday, June 16th. They issued a “buy” rating and a $16.00 price objective for the company.

Ardelyx Stock Performance

Shares of ARDX stock opened at $4.00 on Tuesday. The company has a debt-to-equity ratio of 1.37, a current ratio of 3.49 and a quick ratio of 3.28. The company’s fifty day moving average price is $5.37 and its two-hundred day moving average price is $6.08. The firm has a market capitalization of $988.12 million, a P/E ratio of -18.18 and a beta of 0.70. Ardelyx has a 12 month low of $3.90 and a 12 month high of $8.40.

Ardelyx (NASDAQ:ARDX) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). Ardelyx had a negative return on equity of 35.57% and a negative net margin of 12.35%.The business had revenue of $120.88 million for the quarter, compared to analysts’ expectations of $121.03 million. During the same period in the previous year, the firm posted ($0.08) earnings per share. The firm’s revenue was up 34.3% compared to the same quarter last year. On average, research analysts anticipate that Ardelyx will post -0.1 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Mike Kelliher sold 7,248 shares of the company’s stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $6.27, for a total transaction of $45,444.96. Following the completion of the sale, the insider directly owned 357,418 shares of the company’s stock, valued at $2,241,010.86. This represents a 1.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Eric Duane Foster sold 7,998 shares of the firm’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $6.27, for a total transaction of $50,147.46. Following the completion of the transaction, the insider owned 417,972 shares of the company’s stock, valued at approximately $2,620,684.44. The trade was a 1.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 24,572 shares of company stock worth $154,066 over the last quarter. Insiders own 5.30% of the company’s stock.

Institutional Trading of Ardelyx

Several hedge funds and other institutional investors have recently modified their holdings of ARDX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Ardelyx by 2.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 159,061 shares of the biopharmaceutical company’s stock worth $781,000 after acquiring an additional 4,436 shares during the period. Goldman Sachs Group Inc. grew its position in Ardelyx by 10.3% in the first quarter. Goldman Sachs Group Inc. now owns 2,378,738 shares of the biopharmaceutical company’s stock worth $11,680,000 after acquiring an additional 221,486 shares in the last quarter. Focus Partners Wealth acquired a new position in Ardelyx during the first quarter worth $72,000. Strs Ohio acquired a new position in shares of Ardelyx during the 1st quarter valued at about $135,000. Finally, Legal & General Group Plc grew its holdings in Ardelyx by 13.5% during the second quarter. Legal & General Group Plc now owns 275,344 shares of the biopharmaceutical company’s stock valued at $1,080,000 after purchasing an additional 32,738 shares during the last quarter. Institutional investors and hedge funds own 58.92% of the company’s stock.

Trending Headlines about Ardelyx

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: Second-quarter revenue increased 34.3% year over year to approximately $120.9 million, indicating continued commercial growth despite missing the revenue estimate slightly. Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: BTIG Research maintained a Buy rating on ARDX, suggesting substantial long-term upside potential even after reducing its price target from $17 to $14. BTIG Research price target update
• Neutral Sentiment: Ardelyx’s Q2 earnings call and business update provided additional discussion of operating performance and company priorities, but the available report does not identify a specific new catalyst driving the stock. Ardelyx Q2 2026 Earnings Call Transcript
• Negative Sentiment: Ardelyx reported a second-quarter loss of $0.07 per share, worse than the expected loss of $0.05, although it improved from a $0.08 loss in the year-ago quarter. Revenue of $120.88 million also narrowly missed estimates of approximately $121.0 million. Ardelyx Reports Q2 Loss, Lags Revenue Estimates
• Negative Sentiment: Zacks added ARDX to its Rank #5, or Strong Sell, list, adding to near-term pressure from the earnings miss and the company’s continuing negative profitability metrics. New Strong Sell Stocks for August 7th
• Negative Sentiment: The lower BTIG price target reflects reduced near-term expectations, even though the firm retained its Buy rating. BTIG Research price target update

Ardelyx Company Profile

Ardelyx, Inc (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.